Navigation Links
InDex Pharmaceuticals Gets Patent for Additional DIMS Compounds Granted in the US
Date:3/14/2017

STOCKHOLM, March 14, 2017 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that a patent covering 19 compounds from the company's DIMS platform has been granted by the United States Patent and Trademark Office (USPTO).

InDex has a discovery stage portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new US patent, entitled Methods for identifying biologically active oligonucleotides capable of modulating the immune system (patent number 9593337), covers both the composition-of-matter and method-of-use of 19 different DIMS compounds for the treatment of inflammatory diseases, cancer and infectious diseases. The patent was filed in 2011 and provides an exclusivity period until December 2031, with the possibility of up to 5 years term extension after market approval.

"We continue the work to broaden our preclinical DIMS portfolio in parallel with the clinical development of our lead drug candidate cobitolimod," said Peter Zerhouni, CEO of InDex Pharmaceuticals. "This new patent further strengthens our robust intellectual property portfolio and we are very pleased that the USPTO confirms the novelty of our DIMS platform."

InDex's DIMS compunds are synthetic oligonucleotides that function as immunomodulatory agents by targeting Toll-like receptor 9 (TLR9). DIMS mimic bacterial DNA, without being harmful, and stimulate immune cells to produce beneficial anti-inflammatory cytokines that help to dampen inflammation. This opens up opportunities for the treatment of different inflammatory conditions, in which the immune responses are imbalanced. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis. Besides cobitolimod there are other DIMS candidates that the Company has selected for further preclinical development. InDex has been awarded a grant of SEK 1.8 million for this development from the Swedish innovation agency Vinnova.

For more information:
Peter Zerhouni, CEO
Phone: +46-8-508-847-35
E-mail: peter.zerhouni@indexpharma.com 

InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com

Publication
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on March 14, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/index-pharmaceuticals/r/index-pharmaceuticals-gets-patent-for-additional-dims-compounds-granted-in-the-us,c2211345

The following files are available for download:

http://mb.cision.com/Main/9612/2211345/641834.pdf

PDF

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/index-pharmaceuticals-gets-patent-for-additional-dims-compounds-granted-in-the-us-300423152.html


'/>"/>
SOURCE Index Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. New Access to Vaccines Index Reveals First Landscape of Vaccine Company Actions to Improve Immunisation Coverage
2. InDex Pharmaceuticals Holding AB (publ) Year end Report 2016
3. InDex Pharmaceuticals Enters Agreement With CRO for the CONDUCT Study
4. InDex Pharmaceuticals Will Participate in the European Crohns and Colitis Organisation (ECCO) Congress
5. Cal INDEX and Inland Empire HIE will merge to form Californias largest health information exchange; former White House technology advisor named CEO
6. Aralez Added To The NASDAQ Biotechnology Index
7. Mallinckrodt Pharmaceuticals Earns Top Marks In 2017 Corporate Equality Index
8. CVS Health Achieves 100 Percent on 2017 Corporate Equality Index for Third Consecutive Year
9. Pulmatrix Added to Russell Microcap Index
10. Confidence Wanes as Uncertainty Builds in the Q4 2015 Biopharma CEO Confidence Index
11. Blueprint Medicines Added to NASDAQ Biotechnology Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... COAST, Queensland (PRWEB) , ... October 16, 2018 , ... ... menu, including mocha body scrubs, handmade green clay facials and peppermint foot soaks to ... Saoirse, owner of Ripple Massage. , “We feel our clients still want all the ...
(Date:10/16/2018)... ... October 16, 2018 , ... The iaedp™ ... multidisciplinary group of healthcare treatment providers who treat the full spectrum of eating ... a live, two-day, 12-hour track at Symposium 2019. The courses are regularly ...
(Date:10/13/2018)... ... October 12, 2018 , ... David ... 1987 which was used in the Lockheed F22 Aircraft. Today, he announces the ... uncontrolled AF-Arrhythmia, which can lead to sudden cardiac death (SCD). , The Two-Dimensional ...
Breaking Medicine Technology:
(Date:10/18/2018)... (PRWEB) , ... October 18, ... ... the publication of a research study demonstrating the company’s automated preclinical image ... for optical imaging systems. The technology finds applications in preclinical imaging of ...
(Date:10/17/2018)... (PRWEB) , ... October 17, 2018 , ... The Jacobs ... the California Association of Food Banks at a meeting of its Board of Directors. ... food banks across the State of California. CAFB provides its member food banks with ...
(Date:10/17/2018)... Calif. (PRWEB) , ... October 17, 2018 , ... The Myers’ have been ... p.m. at their office, 11141 Tampa Ave., Northridge, CA 91326. , “The Harvest Festival ... at the same time help the kids at Children’s Hospital LA,” said Kris and Keith. ...
(Date:10/16/2018)... ... October 16, 2018 , ... Balboa Capital , ... and franchise financing , is now recognized by Massage Envy as an ... structure and deliver custom-tailored financing programs to Massage Envy franchisees who need funding ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... recipient of the Academy of Integrative Health and Medicine’s (AIHM) Visionary Award for ... medicine. , Dr. Pizzorno was selected as AIHM’s recipient of the Visionary ...
Breaking Medicine News(10 mins):